• iPSC Cardiomyocytes Differentiation
    • Drug Discovery & Disease Modeling
    • cTnT & SMA
    iPSC Cardiomyocytes Differentiation

Cardiomyocytes Differentiation

We provide top-quality service for directed differentiation of iPSCs into cardiomyocytes using our efficient induction protocol and reagents. We deliver ready-to-use, functional cardiomyocytes that are desirable in vitro models for high content toxicity and drug screening, and cell regeneration research. They are a feasible and physiologically relevant alternative to embryonic stem cells, primary cells, and animal models. 

  • High-quality cardiomyocytes
  • Biomarkers: cTnT & SMA
  • We can generate differentiated cardiomyocytes from iPSC derived from healthy or disease patient samples
  • Fast turnaround time

Get iPSCs to genetically modify and further differentiate into immune cells? We offer fully customizable iPSC generation from human or non-human tissue samples, and our genome editing experts can use CRISPR or TARGATT™  to genetically alter the iPSCs to fit your project requirements. If you need to expedite your experimental timeline, ASC also offers off-the-shelf cardiomyocytes. Contact us today to find the best solution for your projects.

Products and Services
Technical Details

iPSC Differentiation to Cardiomyocytes

 

Timelines: 4-6 weeks

  1. Recovery, Expansion and Validation of iPSCs/ESCs: estimated 3 weeks
  2. Cardiomyocytes Differentiation: estimated 2-4 weeks
  3. Characterization of differentiated cells by immunocytochemical (ICC) staining: 2 biomarkers (cTNT; SMA): estimated 2-4 days
Support Materials
Google